Phillip Md Et Al Frost Purchases 200,000 Shares of OPKO Health, Inc. (NASDAQ:OPK) Stock

OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost acquired 200,000 shares of the business’s stock in a transaction dated Monday, March 17th. The shares were acquired at an average cost of $1.74 per share, with a total value of $348,000.00. Following the transaction, the chief executive officer now owns 213,501,448 shares in the company, valued at approximately $371,492,519.52. This trade represents a 0.09 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Phillip Md Et Al Frost also recently made the following trade(s):

• On Friday, February 28th, Phillip Md Et Al Frost bought 67,434 shares of OPKO Health stock. The shares were bought at an average price of $1.71 per share, for a total transaction of $115,312.14.
• On Tuesday, January 28th, Phillip Md Et Al Frost acquired 47,537 shares of OPKO Health stock. The shares were bought at an average cost of $1.47 per share, for a total transaction of $69,879.39.
• On Friday, January 17th, Phillip Md Et Al Frost bought 150,000 shares of OPKO Health stock. The shares were purchased at an average price of $1.47 per share, for a total transaction of $220,500.00.
• On Wednesday, January 15th, Phillip Md Et Al Frost purchased 500,000 shares of OPKO Health stock. The stock was purchased at an average price of $1.48 per share, with a total value of $740,000.00.

OPKO Health Price Performance

NASDAQ OPK traded up $0.07 on Monday, reaching $1.81. The company had a trading volume of 3,491,995 shares, compared to its average volume of 4,567,380. The stock has a market capitalization of $1.22 billion, a PE ratio of -9.53 and a beta of 1.70. OPKO Health, Inc. has a 12 month low of $0.86 and a 12 month high of $2.04. The company has a quick ratio of 2.69, a current ratio of 2.97 and a debt-to-equity ratio of 0.30. The firm’s 50 day moving average price is $1.62 and its 200 day moving average price is $1.57.

OPKO Health (NASDAQ:OPK) last issued its quarterly earnings data on Thursday, February 27th. The biotechnology company reported $0.01 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.09. The firm had revenue of $183.60 million during the quarter, compared to analyst estimates of $155.42 million. OPKO Health had a negative return on equity of 9.76% and a negative net margin of 18.65%. As a group, equities analysts predict that OPKO Health, Inc. will post -0.25 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $3.00 target price on shares of OPKO Health in a report on Wednesday, March 12th. StockNews.com raised OPKO Health from a “sell” rating to a “hold” rating in a research note on Monday, March 3rd. Finally, Barrington Research reissued an “outperform” rating and set a $2.25 target price on shares of OPKO Health in a research note on Wednesday, March 12th.

Institutional Trading of OPKO Health

Several hedge funds have recently modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of OPKO Health by 4.5% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 186,783 shares of the biotechnology company’s stock valued at $275,000 after acquiring an additional 8,064 shares during the last quarter. Two Sigma Advisers LP lifted its stake in shares of OPKO Health by 2.3% in the 4th quarter. Two Sigma Advisers LP now owns 381,197 shares of the biotechnology company’s stock valued at $560,000 after purchasing an additional 8,396 shares during the last quarter. FMR LLC boosted its holdings in shares of OPKO Health by 103.6% in the 3rd quarter. FMR LLC now owns 21,795 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 11,089 shares during the period. Wealth Enhancement Advisory Services LLC increased its position in shares of OPKO Health by 75.3% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 28,908 shares of the biotechnology company’s stock valued at $42,000 after purchasing an additional 12,417 shares during the last quarter. Finally, Comerica Bank raised its holdings in OPKO Health by 18.2% during the 4th quarter. Comerica Bank now owns 106,369 shares of the biotechnology company’s stock valued at $156,000 after buying an additional 16,369 shares during the period. 64.63% of the stock is owned by hedge funds and other institutional investors.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.